©2025 Stanford Medicine
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Not Recruiting
Trial ID: NCT00250432,
Purpose
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)
Official Title
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults
Stanford Investigator(s)
Dora Ho
Clinical Professor, Medicine - Infectious Diseases
Eligibility
Inclusion Criteria:
* Clinical and Laboratory evidence of blood stream \&/or systemic candida infections
Exclusion Criteria:
* Possible candida contamination
* Candida colonization (non invasive infection), urine, cardiac, bone or brain and prosthetic device infections
* Acute or moderately severe liver disease
* Abnormal liver function tests
* Abnormal blood clotting for patients on blood thinners
Intervention(s):
drug: caspofungin acetate
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joanna Schaenman